SuperworthThermo Fisher Scientific revenue TMO
Sales by quarter and over the last twelve months, from 1995.
- Last 12 months, to Sep 26, 2026
- $47.4B
- Latest quarter, Q3 FY26
- $12.1B
- +9% on a year earlier
- Fiscal year 2025
- $44.6B
- +4% on the year before
Thermo Fisher Scientific's revenue was $47.4B over the twelve months to Sep 26, 2026, up 8% on a year earlier.
In its latest quarter, Q3 FY26, it was $12.1B, up 9% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 7% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $44.6B | +4% |
| FY2024 | $42.9B | +0% |
| FY2023 | $42.9B | −5% |
| FY2022 | $44.9B | +15% |
| FY2021 | $39.2B | +22% |
| FY2020 | $32.2B | +26% |
| FY2019 | $25.5B | +5% |
| FY2018 | $24.4B | +16% |
| FY2017 | $20.9B | +14% |
| FY2016 | $18.3B | +8% |
| FY2015 | $17B | +0% |
| FY2014 | $16.9B | +29% |
| FY2013 | $13.1B | +5% |
| FY2012 | $12.5B | +8% |
| FY2011 | $11.6B | +9% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $12.1B | +9% | $47.4B | |
| Q2 FY26 | $12B | +10% | $46.3B | |
| Q1 FY26 | $11B | +6% | $45.2B | |
| Q4 FY25 | $12.2B | +7% | $44.6B | |
| Q3 FY25 | $11.1B | +5% | $43.7B | |
| Q2 FY25 | $10.9B | +3% | $43.2B | |
| Q1 FY25 | $10.4B | +0% | $42.9B | |
| Q4 FY24 | $11.4B | +5% | $42.9B | |
| Q3 FY24 | $10.6B | +0% | $42.4B | |
| Q2 FY24 | $10.5B | −1% | $42.3B | |
| Q1 FY24 | $10.3B | −3% | $42.5B | |
| Q4 FY23 | $10.9B | −5% | $42.9B |
Against its peers
Companies in Medical - Diagnostics & Research nearest Thermo Fisher Scientific's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| TMOThermo Fisher Scientific | $47.4B | +8% a year |
| DHRDanaher | $25.1B | +5% a year |
| AAgilent Technologies | $7.4B | +9% a year |
| IQVIQVIA | $17B | +8% a year |
| WATWaters | $4.6B | +52% a year |
| IDXXIDEXX Laboratories | $4.6B | +13% a year |
| ILMNIllumina | $4.5B | +5% a year |
| MTDMettler-Toledo International | $4.1B | +7% a year |
| DGXQuest Diagnostics | $11.6B | +9% a year |
| LHLabcorp | $14.3B | +6% a year |
| Peer median | $7.4B |
Where Thermo Fisher Scientific ranks
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Thermo Fisher Scientific
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.